CGON
CG Oncology, Inc. Common stock
NASDAQ · USHealthcareBiotechnology
$70.19-2.31%
Price as of Jul 20, 2026
CGON financials
CG Oncology, Inc. Common stock financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $4.0M | $1.1M | $204.0K | $191.0K |
| Cost of revenue | $4.6M | $82.1M | $45.8M | $15.0K |
| Gross profit | -$607.0K | -$81.0M | -$45.5M | $176.0K |
| Operating expenses | $190.2M | $33.7M | $9.9M | $35.4M |
| Operating income | -$190.8M | -$114.7M | -$55.4M | -$35.2M |
| Net income | -$161.0M | -$88.0M | -$48.6M | -$35.4M |
| EBITDA | -$159.6M | -$88.0M | -$48.6M | -$35.4M |
| Basic EPS | $-2.08 | $-1.41 | $-1.02 | $-0.66 |
| Diluted EPS | $-2.08 | $-1.41 | $-1.02 | $-0.66 |
| Balance sheet | ||||
| Cash & equivalents | $32.5M | $257.1M | $8.3M | $88.1M |
| Total assets | $791.6M | $754.8M | $199.3M | $147.7M |
| Total liabilities | $39.0M | $21.4M | $14.5M | $22.6M |
| Stockholders’ equity | $752.6M | $733.4M | $184.8M | $125.2M |
| Total debt | $7.0M | $238.0K | $1.0M | $15.9M |
| Net debt | -$25.5M | -$256.8M | -$7.2M | -$72.2M |
| Cash flow | ||||
| Operating cash flow | -$132.3M | -$78.7M | -$45.7M | -$29.8M |
| Capital expenditure | -$134.0K | -$234.0K | $0.00 | -$14.0K |
| Free cash flow | -$132.5M | -$78.9M | -$45.7M | -$29.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |